Reversible Sol–Gel Transition in Thermoresponsive Collagen Hydrogels for Cryogen-Free Cell Logistics
Gels · 02.06.2026 · 12 (6) · 488
DOI: 10.3390/gels12060488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gels, online erschienen am 02.06.2026. Verfasst von Junjie Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, No. 29 Wangjiang Road, Chengdu 610065, …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, 111 Project of Introducing Talents of Discipline to Universities, 111 Project of Introducing Talents of Discipline to Universities, China.
Abstract (Originalsprache)
Cell culture is foundational to biomedical advancements, yet its widespread clinical and practical distribution is severely constrained by the high infrastructural costs of cryogenic logistics and the physical stressors of liquid-phase transit. Herein, we propose a proof-of-concept cryogen-free cell transportation strategy leveraging a rapid reversible thermoresponsive collagen (RRTC) hydrogel regulated by simulated body fluid (SBF). Operating via temperature-driven physical network assembly and disassembly rather than chemical crosslinking or chemical modifications, the RRTC system undergoes a rapid sol-to-gel transition within 60 s at 37 °C for efficient cell encapsulation, and completely reverses to a free-flowing sol state within 60 s at 4 °C to facilitate enzyme-free, non-destructive cell retrieval. Using L929 fibroblasts as a standardized benchmarking cell model, the biophysical protection of the matrix was systematically evaluated under both static simulated transit (48 h and 120 h) and real-world trans-city courier transportation (an approximate 50 h round trip via SF Express) within a passively temperature-shield configuration. The SBF-regulated 3D physical confinement successfully shielded cells from manual handling, multi-axis shipping vibrations, and environmental thermal fluctuations. Post-transport evaluations demonstrated that the encapsulated cells maintained a high viability above 90% and a stable recovery yield of approximately 78%, while exhibiting robust subsequent 2D re-adhesion and sustained re-culture capacity. This thermoresponsive matrix provides a potential matrix for short-term cryogen-free cell transportation and post-transport recovery, while further studies using additional cell types, longer transportation periods, and functional assays are required to evaluate its broader applicability.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, No. 29 Wangjiang Road, Chengdu 610065, China.
- Institute of Biomedical Innovation, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, No. 1299, Xuefu Road, Honggutan District, Nanchang 330031, China.
ORCID-Profile: Yang Lei, Jieyu Zhang, Yunbing Wang
Förderung
- National Natural Science Foundation of China
- 111 Project of Introducing Talents of Discipline to Universities
- 111 Project of Introducing Talents of Discipline to Universities, China
Zitieren
APA
Wang, J., Ju, Y., Lei, Y., Zhang, J., & Wang, Y. (2026). Reversible Sol–Gel Transition in Thermoresponsive Collagen Hydrogels for Cryogen-Free Cell Logistics. Gels, 12(6), 488. https://doi.org/10.3390/gels12060488
Vancouver
Wang J, Ju Y, Lei Y, Zhang J, Wang Y. Reversible Sol–Gel Transition in Thermoresponsive Collagen Hydrogels for Cryogen-Free Cell Logistics. Gels. 2026;12(6):488. doi:10.3390/gels12060488
BibTeX
@article{Wang2026,
author = {Wang, Junjie and Ju, Yi and Lei, Yang and Zhang, Jieyu and Wang, Yunbing},
title = {Reversible Sol–Gel Transition in Thermoresponsive Collagen Hydrogels for Cryogen-Free Cell Logistics},
journal = {Gels},
year = {2026},
volume = {12},
number = {6},
pages = {488},
doi = {10.3390/gels12060488}
}
EUVIMED